Zafgen (Nasdaq: ZFGN) 37.5% LOWER; announced that it received verbal notice late yesterday from the U.S. Food and Drug Administration ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Special Reports

UBS Cuts Price Target Ahead of Quanta Services (PWR) 3Q Results October 20, 2015 10:47 AM Baird Remains Bullish as Market Reacts to Cempra's (CEMP) 2nd Phase 3 Study of Solithromycin October 19, 2015 10:17 AM Roth Capital Cuts Price Target on Cempra (CEMP) as Solithromycin Misses High Expectations October 19, 2015 8:53 AM Cowen Cuts Price Target on Zafgen (ZFGN) as Beloranib is Placed on Hold Following Patient Death October 16, 2015 1:28 PM SOLITAIRE-IV Data Not as Strong as ORAL; Leerink Partners Cuts Price Target on Cempra's (CEMP) to $21 October 16, 2015 1:13 PM